An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

NCT01511393 · Enrolling by invitation

Last updated 2026-05-28

This clinical trial monitors the annual occurrence of medullary thyroid carcinoma in U.S. adults to check for any potential rise linked to the use of diabetes medications like liraglutide and exenatide.

Status Enrolling by invitation Only people invited by the researchers can join.

Type Observational

Participants 6,750 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2012-01 · est. completion 2039-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01511393 ↗

Description as written by the study sponsor.

This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new adult cases of medullary thyroid carcinoma (MTC) and to establish a registry for these new cases in order to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.

Treatments tested

No treatment given Other

None. Non-interventional study.

Main thing measured	Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01511393 ↗